Ipsen SA (IPSEF)
125.37
0.00 (0.00%)
USD |
OTCM |
Dec 27, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 10.37B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 16.14% |
| Valuation | |
| PE Ratio | 14.27 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.832 |
| Price to Book Value | 2.452 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.296 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries. |
| URL | https://www.ipsen.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 07, 2025 (est.) |
| Last Earnings Release | Jul. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 30, 2024 |
Ratings
Profile
| Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries. |
| URL | https://www.ipsen.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Feb. 07, 2025 (est.) |
| Last Earnings Release | Jul. 25, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 30, 2024 |